ALDEYRA THERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $4.80 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-15
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $4.80M, a 438.56% increase year-over-year.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$8.11M, a 714.42% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$3.63M, a 740.23% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $648.52K.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$10.20M.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$225.23K.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$13.04M.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$14.06K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 116 month |
|---|---|---|---|---|---|
| 2018-03-31 | $4.80M 10-Q · filed 2018-05-15 | -$3.31M derived: sum of 2 quarters · filed 2018-05-15 | -$6.94M derived: sum of 3 quarters · filed 2018-05-15 | -$6.29M derived: sum of 4 quarters · filed 2018-05-15 | |
| 2017-12-31 | -$8.11M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | -$11.74M derived: sum of 2 quarters · filed 2018-03-29 | -$11.09M derived: sum of 3 quarters · filed 2018-03-29 | -$10.20M 10-K · filed 2018-03-29 | |
| 2017-09-30 | -$3.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$2.98M derived: sum of 2 quarters · filed 2017-11-09 | -$2.09M 10-Q · filed 2017-11-09 | -$767.92K derived: sum of 4 quarters · filed 2018-03-29 | |
| 2017-06-30 | $648.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $1.54M 10-Q · filed 2017-08-07 | $2.86M derived: sum of 3 quarters · filed 2018-03-29 | $3.43M derived: sum of 4 quarters · filed 2018-03-29 | |
| 2017-03-31 | $891.54K 10-Q · filed 2018-05-15 | $2.21M derived: sum of 2 quarters · filed 2018-03-29 | $2.78M derived: sum of 3 quarters · filed 2018-03-29 | $675.54K derived: sum of 4 quarters · filed 2018-03-29 | |
| 2016-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $1.89M derived: sum of 2 quarters · filed 2018-03-29 | -$216.00K derived: sum of 3 quarters · filed 2018-03-29 | -$225.23K 10-K · filed 2018-03-29 | |
| 2016-09-30 | $566.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$1.54M derived: sum of 2 quarters · filed 2017-11-09 | -$1.55M 10-Q · filed 2017-11-09 | -$14.50M derived: sum of 4 quarters · filed 2017-11-09 | |
| 2016-06-30 | -$2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | -$2.11M 10-Q · filed 2017-08-07 | -$15.06M derived: sum of 3 quarters · filed 2017-05-15 | -$15.12M derived: sum of 4 quarters · filed 2017-05-15 | |
| 2016-03-31 | -$9.23K 10-Q · filed 2017-05-15 | -$12.96M derived: sum of 2 quarters · filed 2017-05-15 | -$13.01M derived: sum of 3 quarters · filed 2017-05-15 | -$13.04M derived: sum of 4 quarters · filed 2017-05-15 | |
| 2015-12-31 | -$12.95M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$13.00M derived: sum of 2 quarters · filed 2017-03-30 | -$13.03M derived: sum of 3 quarters · filed 2017-03-30 | -$13.04M 10-K · filed 2017-03-30 | |
| 2015-09-30 | -$54.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$84.68K derived: sum of 2 quarters · filed 2016-11-14 | -$86.12K 10-Q · filed 2016-11-14 | -$94.07K derived: sum of 4 quarters · filed 2016-11-14 | |
| 2015-06-30 | -$30.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | -$31.88K 10-Q · filed 2016-08-10 | -$39.83K derived: sum of 3 quarters · filed 2016-08-10 | ||
| 2015-03-31 | -$1.44K 10-Q · filed 2016-05-09 | -$9.40K derived: sum of 2 quarters · filed 2016-05-09 | |||
| 2014-12-31 | -$7.96K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$14.06K 10-K · filed 2016-03-30 | |||
| 2014-09-30 | -$6.11K 10-Q · filed 2015-11-13 | ||||
| 2014-03-31 | -$7.94K 10-Q · filed 2014-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |